Jim Cramer Endorses AstraZeneca, Shares Jump 3.06% on Cancer Franchise Strength
Jim Cramer said he wants every drug stock including AstraZeneca, praising its cancer franchise as stronger than expected and recommending holding it over AbbVie ahead of its Q4 report. AstraZeneca shares jumped 3.06% on the endorsement in heavy earnings rotation with DuPont, Coca-Cola, CVS Health, Datadog and S&P Global.
1. Cramer Comments on AstraZeneca
On February 10, Jim Cramer highlighted AstraZeneca as one of the drug stocks he wants investors to hold, citing its stronger-than-expected cancer franchise and steady dividend. He advised a caller to keep AZN shares rather than switch to AbbVie, noting an upcoming Q4 earnings report for both companies.
2. Share Reaction and Market Context
Following the endorsement, AstraZeneca shares rose 3.06% as part of a broader earnings-focused segment that also featured DuPont, Coca-Cola, CVS Health, Datadog and S&P Global. The positive sentiment underscores investor interest in AZN’s oncology pipeline and dividend yield.